EKF Diagnostics Holdings plc

Equities

EKF

GB0031509804

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 11:35:04 2024-04-26 am EDT			5-day change	1st Jan Change
27.6 ^GBX	-0.72%		+0.73%	-12.80%

Apr. 11	Onward Opportunities' small-cap strategy yields solid results in 2023	AN
Mar. 20	EKF Diagnostics says prospects "promising" but pauses dividends	AN

EKF Diagnostics announces enzyme fermenter progress

June 20, 2023 at 07:02 am EDT

EKF Diagnostics Holdings PLC - Penarth, Wales-based diagnostics company - Says its Life Sciences division's new 14,500 litre enzyme fermenter has successfully completed factory acceptance testing. Notes it will be the largest fermenter in its capacity expansion programme. Says fermenter is scheduled for delivery in June and its installation will be completed in the third quarter of 2023. Adds validation processes have begun for the new 65L, 300L, 1,500L and 3,000L fermenters at its South Bend facility in Indiana.

Executive Chair Julian Baines says: "We're delighted that we continue to make good progress on our capacity expansion plans. We remain on track to have all of our new fermentation capacity in South Bend installed and validated towards the end of the third quarter of 2023, with all but the largest fermenter becoming operational over the summer."

Current stock price: 36.20 pence, down 2.2% on Tuesday

12-month change: up 7.7%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about EKF Diagnostics Holdings plc

Onward Opportunities' small-cap strategy yields solid results in 2023	Apr. 11	AN
EKF Diagnostics says prospects "promising" but pauses dividends	Mar. 20	AN
EKF Diagnostics Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
EKF Diagnostics reports trading in line with expectations	Jan. 29	AN
EKF Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2023	Jan. 29	CI
EKF Diagnostics Holdings plc Announces the Official Opening of its New State-Of-The-Art Life Sciences Manufacturing Site in South Bend, Indiana, United States	23-10-26	CI
EARNINGS: FireAngel Safety interim loss widens amid ongoing headwinds	23-09-26	AN
Earnings Flash (EKF.L) EKF DIAGNOSTICS HOLDINGS Reports H1 Revenue GBP26.9M	23-09-26	MT
EKF Diagnostics Holdings plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
FTSE 100 Closes Tuesday Up 0.41% as Oil-Price Rises Benefit the Index	23-09-12	DJ
EKF Diagnostics hires CFO from Trellus Health, latter names successor	23-09-12	AN
FTSE 100 Rises, Led by AB Foods; Smurfit Kappa Slides	23-09-12	DJ
Trellus Health's Interim Finance Head Takes Full-time CFO Role at EKF Diagnostics	23-09-12	MT
EKF Diagnostics Holdings plc Provides Financial Guidance for the Year Ending 31 December 2023	23-09-12	CI
EKF Diagnostics Holdings plc Appoints Stephen Young as Chief Financial Officer	23-09-12	CI
Revolution Bars reports good progress from Peach Pubs	23-07-26	AN
FTSE 100 Closes Down 0.2% as Miners Offset Ocado, -2-	23-07-26	DJ
FTSE 100 Closes Up 0.5% as Sage Group Shines	23-06-28	DJ
SONIA Illiquidity Could Explain Disconnect in BOE Peak Rate Pricing	23-06-28	DJ
EKF Diagnostics says CFO Davies resigns to pursue other opportunities	23-06-28	AN
EKF Diagnostics CFO Plans Exit; Successor to Assume Role in Q4	23-06-28	MT
Marc Davies to Step Down as Chief Financial Officer of EKF Diagnostics Holdings plc	23-06-28	CI
EKF Diagnostics announces enzyme fermenter progress	23-06-20	AN
EKF Diagnostics' Enzyme Fermenter Completes Factory Acceptance Testing	23-06-20	MT
EKF Diagnostics Holdings plc Announces Its Life Sciences Division's New 14,500L Enzyme Fermentation Capacity Expansion Progress	23-06-20	CI

Chart EKF Diagnostics Holdings plc

Duration

Period

More charts

Company Profile

EKF Diagnostics Holdings plc is a United Kingdom-based diagnostics company. The Company is engaged in point-of-care testing, central laboratory tests, enzyme manufacturing and the provision of contract manufacturing services to the healthcare industry. Its principal activity is the development, manufacture and supply of products into the in-vitro diagnostics marketplace. Its point of care analyzers is designed for use within doctors' surgeries, clinics, blood banks and hospital and private laboratories to provide results. Its life sciences specialize in producing enzymes and contracted custom products for use in medical diagnostics, pharmaceuticals and industry. Its life science facilities are based in two locations in Indiana, United States. Its central laboratory division manufactures a spectrum of reagents for use in hospital laboratories. Its contract manufacturing business provides specialized services to the diagnostics and healthcare industries for the production of custom kits.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-14 - Annual General Meeting

More about the company